Investors and Media

Press Releases

September 2, 2026

Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial

August 27, 2026

Scholar Rock to Present at Upcoming Investor Conferences

August 21, 2026

Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan

August 14, 2026

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 7, 2026

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date

August 6, 2026

Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights

July 29, 2026

Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference

July 20, 2026

Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)

Archived Press Releases